Previous studies have indicated that the risk of HF readmission significantly increased in patients with higher concentration of BNP or NT-proBNP, more severe NYHA class, high proportion of rehospitalization for HF, and multiple comorbidities, such as hyperkalaemia (probably discontinuing ACEI/ARB or mineralocorticoid receptor antagonist, MRA), poor renal function or pulmonary infection [32–35]. This evidence concerns the gene NR3C2 and hydrops fetalis.